Document is current
Any future updates will be listed below
-
Authors
Cao, Mengdie
Katial, Rohit
Liu, Yanjun
Lu, Xiaoyu
Gu, Qin
Chen, Chen
Liu, Katie
Zhu, Zhen
Marshall, Mark R.
Yu, Yanxia https://orcid.org/0000-0001-6105-0114
Wang, Zheng https://orcid.org/0009-0005-7293-0949
-
Funding
Funding for this research was provided by:
Shanghai Bao Pharmaceuticals Co., Ltd. was the formal sponsor and funder of the clinical trial.
- License Information
-
More Information
Article History
Received: 6 May 2024
Revised: 14 December 2024
Accepted: 3 January 2025
First Online: 18 January 2025
Competing interests
: ZW, ZZ, YL are employees of Shanghai Bao Pharmaceuticals Co., Ltd, and own stock/other equities. Other authors declare no competing interests.
: Both phase 1 clinical trials of KJ103 were approved separately by the ethics committee of the “New Zealand Clinical Research” (Protocol no. SHBJ-2021-001) and “Suzhou Municipal Hospital” (Protocol no. SHBJ-2021-002). All subjects signed written informed consent before undergoing any study-specific procedures.
